Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-28 · accession 0000886163-22-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-01 | 2022-02-28 | LGND | KOZARICH JOHN W | Dir | M - OptEx | $12.53 | +7,335 | 42.1K | +21% | +$91.9K |
| D | 2022-03-01 | 2022-02-28 | LGND | KOZARICH JOHN W | Dir | S - Sale+OE | $102.62 | -908 | 41.2K | -2% | -$93.2K |
| D | 2022-03-01 | 2022-02-28 | LGND | KOZARICH JOHN W | Dir | M - OptEx | $0.00 | -7,335 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-28 | M | A | 7,335 | $12.53 | 42,117 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-28 | S | D | 908 | $102.62 | 41,209 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-02-28 | M | D | 7,335 | $0.00 | 0 | D | $12.53 · — to 2022-05-31 | 7,335 Common Stock | (F1) Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date. |